ORIGINAL RESEARCH article
Front. Med.
Sec. Precision Medicine
This article is part of the Research TopicPrecision Medicine in Cardiovascular Remodeling: Bridging Pathogenesis to Personalized Therapeutic StrategiesView all 4 articles
Different beta-blockers for preventing arrhythmic events in patients with long QT syndrome: A Network meta-analysis
Provisionally accepted
- 1The Second Clinical Medical School of Zhengzhou University, Zhengzhou, China
- 2Nanchang University Queen Mary School, Nanchang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective：This study aims to compare the efficacy of different types of beta-blockers in preventing arrhythmias in patients with long QT syndrome (LQTS), and simultaneously analyze the relationship between dose and effect within each drug by incorporating dose as a continuous covariate. Methods：A systematic search was conducted in the electronic database, with the cutoff date set at July 20, 2025. The search scope was limited to observational studies that compared at least two drug strategies. A Bayesian arm random-effects network meta-analysis (NMA) was performed, in which the daily equivalent dose (mg/day) was included as a continuous covariate to explore the dose-response relationship. Results：This analysis included 5,692 patients with LQTS from 10 cohort studies. In LQT1, nadolol was superior to propranolol (RR=0.59, 95% CI: 0.39–0.90) and had the highest probability of being the optimal treatment (SUCRA=0.92). Dose-response trends for all drugs were non-significant (all P>0.05). For LQT2, no beta-blocker showed significant superiority, though nadolol (SUCRA=0.78) and propranolol (SUCRA=0.65) were ranked highest; nadolol alone demonstrated a significant dose-effect relationship (slope=-0.01763, P=0.010). In LQT3, no active treatment differed significantly from atenolol, yet SUCRA values favored nadolol (0.85) and propranolol (0.75). A significant dose-response was observed for nadolol (slope=-0.02136, P=0.023). An unexpected risk reduction was noted for placebo versus atenolol (RR=0.63, 95% CI: 0.42–0.93, P=0.02), likely due to baseline imbalances. Evidence consistency (node split P>0.38) and sensitivity analyses supported the robustness of these findings. Conclusions：Nadolol demonstrates significant and consistent clinical advantages in LQT1 patients and should be considered as first-line therapy for this subtype. In LQT2 patients, nadolol not only shows a superiority trend but also has a significant dose-effect relationship, supporting its clinical priority; in LQT3 patients, nadolol exhibits a significant dose-dependent risk reduction trend, though no statistically significant differences in efficacy were observed among all beta-blockers. Additionally, LQT3 patients should be cautious of the potential risks associated with atenolol.
Keywords: Long Q-T syndrome, beta-blockers, LQT1/2/3, Cardiac events, Dose-response relationship
Received: 23 Oct 2025; Accepted: 28 Nov 2025.
Copyright: © 2025 Jiang, Zhang, Xiong, Li, Su, Zhu and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yinchuan Zhu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.